Skip to main content

Carboplatin Disease Interactions

There are 5 disease interactions with carboplatin:

Major

Antineoplastics (applies to carboplatin) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.
  3. "Product Information. Fludara (fludarabine)." Berlex, Richmond, CA.
  4. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
  5. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  6. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
  7. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb, Princeton, NJ.
  8. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
  9. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  10. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.
  11. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
  12. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome, Research Triangle Pk, NC.
  13. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  14. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.
  15. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn, Kalamazoo, MI.
  16. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
  17. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.
  18. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
  19. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
  20. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb, Princeton, NJ.
  21. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
  22. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
  23. "Product Information. Tabloid (thioguanine)." Prasco Laboratories, Cincinnati, OH.
  24. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb, Princeton, NJ.
  25. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  26. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
  27. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
  28. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
  29. "Product Information. Nipent (pentostatin)." Hospira Inc, Lake Forest, IL.
  30. "Product Information. DTIC-Dome (dacarbazine)." Bayer, West Haven, CT.
  31. "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation), Eatontown, NJ.
View all 31 references
Major

Carboplatin (applies to carboplatin) bleeding disorders

Major Potential Hazard, High plausibility.

The use of carboplatin is contraindicated in patients with significant bleeding. Carboplatin causes severe myelosuppression and dose-dependent thrombocytopenia. Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, epistaxis, hemoptysis, hematuria, and melena. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Paraplatin (carboplatin)." Bristol-Myers Squibb, Princeton, NJ.
Major

Carboplatin (applies to carboplatin) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Fever

The use of carboplatin is contraindicated in patients with severe myelosuppression. Carboplatin induces dose-dependent leukopenia, thrombocytopenia, and anemia, which is cumulative and also dose limiting. Therapy with carboplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation, whose marrow function is recovering from previous cytotoxic therapy, or in patients with compromised renal function. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Peripheral blood counts should be frequently monitored during carboplatin injection treatment and, when appropriate, until recovery is achieved.

References

  1. "Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Major

Carboplatin (applies to carboplatin) renal dysfunction

Major Potential Hazard, High plausibility.

Carboplatin is primarily eliminated by the kidney. Total body and renal clearance of carboplatin are reduced in patients with a creatinine clearance < 60 mL/min. Patients with impaired renal function are at increased risk for toxicity, particularly myelosuppression. Therapy with carboplatin should be administered cautiously in patients with compromised renal function. Clinical monitoring of renal function is recommended.

References

  1. "Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Minor

Carboplatin (applies to carboplatin) peripheral neuropathy

Minor Potential Hazard, High plausibility.

Mild peripheral neuropathy has been noted during carboplatin therapy and is characterized most frequently by paresthesias. Patients older than 65 years and/or previously treated with cisplatin appear to be at increased risk for peripheral neuropathy. There was no worsening of cisplatin symptoms in 70% of patients who received carboplatin as secondary treatment. Therapy with carboplatin should be administered cautiously in patients with or predisposed to neuropathy.

References

  1. "Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.

Carboplatin drug interactions

There are 297 drug interactions with carboplatin

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.